EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Augmentation Therapy With Serotonin 5‐ HT 1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies

Risa Yamada, Ayumu Wada, Andrew Stickley, Adrian Newman‐Tancredi, Tomiki Sumiyoshi

Neuropsychopharmacology Reports · 2025-06 · 45 (2)

DOI: 10.1002/npr2.70023 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Objective The use of serotonin 5‐HT 1A receptor partial agonists (5‐HT 1A ‐PAs) as an add‐on therapy has been associated with the enhancement of attention/processing speed in patients with schizophrenia. Also, 5‐HT 1A receptors have been shown to play a role in the pathophysiology of mood disorders. There is compelling evidence supporting that stimulation of 5‐HT 1A receptors accelerates antidepressant effects. Accordingly, this systematic review examines the ability of adjunctive treatment with 5‐HT 1A ‐PAs to improve cognitive function in patients with depressive symptoms. Methods A literature search using PubMed, the Cochrane Library, and Web of Science databases was performed from 1987 to January 2024 to identify randomized controlled trials (RCTs) corresponding to the following inclusion criteria: (1) RCTs, (2) human studies; studies that (3) targeted patients with a psychiatric disorder (except for schizophrenia or schizoaffective disorder), (4) evaluated the effect of cognitive functions, (5) were written in English. Results From the 80 studies initially screened, three met the inclusion criteria. Two of these studies dealt with vascular depression while one focused on major depressive disorder (MDD). In MDD, combined treatment with buspirone and melatonin was more efficacious in ameliorating subjective cognitive disturbances compared to the use of buspirone alone or the use of a placebo. Likewise, the combination of escitalopram–tandospirone was more advantageous than escitalopram alone for improving executive function and verbal fluency in patients with vascular depression. Conclusions Further studies with novel 5‐HT 1A receptor agonists are warranted to examine their potentially more robust benefits on cognitive performance in subjects suffering from mood deficits.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →